Bernstein Upgrades Biomarin Pharmaceutical to Outperform, Raises Price Target to $110
Portfolio Pulse from Benzinga Newsdesk
Bernstein analyst William Pickering has upgraded Biomarin Pharmaceutical (NASDAQ:BMRN) from Market Perform to Outperform, raising the price target from $94 to $110.
August 20, 2024 | 9:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bernstein has upgraded Biomarin Pharmaceutical to Outperform and increased the price target to $110, indicating a positive outlook on the stock.
The upgrade from Market Perform to Outperform by a reputable analyst like Bernstein suggests increased confidence in Biomarin's future performance. The raised price target to $110 indicates potential upside, likely leading to positive investor sentiment and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100